Epizyme (Epizyme) Cash-to-Debt : 0.61 (As of Jun. 2022)

View and export this data going back to 2013. Start your Free Trial

What is Epizyme Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Epizyme's cash to debt ratio for the quarter that ended in Jun. 2022 was 0.61.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Epizyme couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2022.

The historical rank and industry rank for Epizyme's Cash-to-Debt or its related term are showing as below:

EPZM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.61 Med: 292.38 Max: No Debt
Current: 0.61

During the past 11 years, Epizyme's highest Cash to Debt Ratio was No Debt. The lowest was 0.61. And the median was 292.38.

EPZM's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.5 vs EPZM: 0.61

Epizyme Cash-to-Debt Historical Data

The historical data trend for Epizyme's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Epizyme Cash-to-Debt Chart

Epizyme Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash-to-Debt

Get a 7-Day Free Trial

2,513.08

No Debt

8.38

1.59

0.74

Epizyme Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Cash-to-Debt	Get a 7-Day Free Trial															1.04	0.92	0.74	0.84	0.61

Competitive Comparison of Epizyme's Cash-to-Debt

For the Biotechnology subindustry, Epizyme's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Epizyme's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Epizyme's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Epizyme's Cash-to-Debt falls into.

Epizyme Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Epizyme's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	176.79	/	(4.154	+	234.958)
	=	0.74

Epizyme's Cash to Debt Ratio for the quarter that ended in Jun. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	144.412	/	(5.282	+	232.431)
	=	0.61

Epizyme (NAS:EPZM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Epizyme Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Epizyme's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Epizyme (Epizyme) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Epizyme Inc (NAS:EPZM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Technology Square, 4th Floor, Cambridge, MA, USA, 02139

Website

https://www.epizyme.com

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing, and commercializing novel epigenetic medicines. Its product candidates include one approved product, TAZVERIK (tazemetostat), an inhibitor of the EZH2. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.

Executives

Jeffery Kutok	officer: Chief Scientific Officer	784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jerald Korn	officer: Chief Operating Officer	128 GORDON RD, NEWTON MA 02468
Joseph Beaulieu	officer: Corporate Controller	C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Shefali Agarwal	officer: Chief Medical Officer	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Royalty Pharma Investments 2019 Icav	director, 10 percent owner	C/O RP MANAGEMENT, LLC 100 E. 59TH ST., 33RD FLOOR NEW YORK NY 10022
Pablo G. Legorreta	director	110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
Carol Stuckley	director	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Roy A Beveridge,	director	500 W MAIN ST, LOUISVILLE KY 40202
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Robert B Bazemore	director, officer: President & CEO	33 HAYDEN AVE, LEXINGTON MA 02421
Matthew Ros	officer: Chief Operating Officer	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Tombesi	officer: Chief Financial Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Victoria Vakiener	officer: Chief Commercial Officer	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Carl Goldfischer	director	161 WEST 61ST STREET, NEW YORK NY 10022
Rp Management, Llc	director	110 EAST 59TH STREET SUITE 3300 NEW YORK NY 10022